Cart
sales@molnova.com
Cdc7-IN-7
CAS No. 1402059-17-9
Cdc7-IN-7( —— )
Catalog No. M32832 CAS No. 1402059-17-9
Cdc7-IN-7 is a potent inhibitor of Cdc7 kinase.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 169 | In Stock |
|
| 5MG | 153 | In Stock |
|
| 10MG | 224 | In Stock |
|
| 25MG | 375 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCdc7-IN-7
-
NoteResearch use only, not for human use.
-
Brief DescriptionCdc7-IN-7 is a potent inhibitor of Cdc7 kinase.
-
DescriptionCdc7-IN-7 (compound I-E) is a potent Cdc7 kinase inhibitor extracted from patent WO2019165473A1, compound I-E. Cdc7 is a serine-threonine protein kinase enzyme which is essential for the initiation of DNA replication in the cell cycle.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetCDK
-
RecptorCDK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1402059-17-9
-
Formula Weight410.42
-
Molecular FormulaC21H22N4O5
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC(OCC1CC1)(=O)C2=C(NN3CCOCC3)OC(=CC=4C=5C(NC4)=NC=CC5)C2=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Christian Andrew HASSIG, et al. Methods of treatment of cancer comprising cdc7 inhibitors. WO2019165473A1.
molnova catalog
related products
-
PF-06873600
PF-06873600 (PF06873600, PF 06873600) is a potent, orally bioavailable inhibitor of cyclin-dependent kinase (CDK) with Ki values of 0.09 nM, 0.13 nM and 0.16 nM for CDK2, CDK4 and CDK6, respectively.
-
Roniciclib
A novel potent, orally active, pan-CDK inhibitor with IC50 of 7/9/11 nM for CDK1/2/4 respectively, inhibits transcriptional CDK9/7 with IC50 of 5-25 nM.
-
(R)-Enitociclib
(R)-Enitociclib, an enantiomer of BAY-1251152, is a CDK9 inhibitor with anticancer activity.
